Hydromorphone (Dilaudid) utilized in an Acute Care Pre/Post Surgical Setting

1. Shannon Henfield
Lamar University
MSNE 5356 Advanced Pharmacology

2.  Pain
 Acute
 Nociceptive
 Somatic
 Visceral
 Neuropathic
 Chronic

3.  Transduction
 Transmission
 Modulation
 Perception

4.  Contraindicated in individuals
 severe asthma or breathing
 a blockage in your stomach or intestines
 a bowel obstruction called paralytic ileus
 pregnant women or breastfeeding

5.  Headache
 Difficulty falling asleep or staying asleep
 Dry mouth
 Lightheadedness
 Drowsiness
 Heavy sweating
 Muscle, back or joint pain, stomach pain
 Anxiety
 Flushing
 Itching
 Depression

6.  Distributed orally, rectally, subcutaneously, or
intravenously
 Five times more potent than morphine
 Half life one to three hours
 Metabolized in the liver

7.  Cytochrome P450
 CYP2D6
 Metabolizers
 Poor metabolizers
 Intermediate metabolizers
 Normal metabolizers
 Ultra rapid metabolizers

8.  Collaborate with pharmacy on dosage
 Collaborate with patient regarding pain scale
and six medication rights
 Collaborate with physician regarding a less
addictive alternative for chronic pain

9.  Notate allergies, PMH, current medications
 Monitor vital signs and labs
 Customize dosage for each patient
 Seek less addictive alternative

10.  Arcangelo, V.P., & Peterson, A.W. (2013). Pharmacotherapeutics for advanced
practice: A practical approach (3rded.). Philadelphia, PA: Lippincott
Williams & Wilkins
 Hydromorphone (2016). U.S. National Library of Medicine. Retrieved from
https://medlineplus.gov/druginfo/meds/a682013.html
 Lim. G. (2016, November 14). Personal interview.
 Sadhasivam, Senthilkumar & Chidambaran, Vidya. (2012).
Pharmacogenomics of opioids and perioperative pain management.
Pharmacogenomics 13(15):1719-1740.
 Smith, H. (2009). Opioid Metabolism, Mayo Clinic Proceedings 84(7), 613-
624.